The treatment landscape in thyroid cancer: a focus on cabozantinib
about
Lenvatinib for Anaplastic Thyroid Cancer.MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials.Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
P2860
The treatment landscape in thyroid cancer: a focus on cabozantinib
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The treatment landscape in thyroid cancer: a focus on cabozantinib
@ast
The treatment landscape in thyroid cancer: a focus on cabozantinib
@en
The treatment landscape in thyroid cancer: a focus on cabozantinib
@nl
type
label
The treatment landscape in thyroid cancer: a focus on cabozantinib
@ast
The treatment landscape in thyroid cancer: a focus on cabozantinib
@en
The treatment landscape in thyroid cancer: a focus on cabozantinib
@nl
prefLabel
The treatment landscape in thyroid cancer: a focus on cabozantinib
@ast
The treatment landscape in thyroid cancer: a focus on cabozantinib
@en
The treatment landscape in thyroid cancer: a focus on cabozantinib
@nl
P2860
P356
P1476
The treatment landscape in thyroid cancer: a focus on cabozantinib
@en
P2093
Maria E Cabanillas
Steven P Weitzman
P2860
P304
P356
10.2147/CMAR.S68373
P407
P577
2015-01-01T00:00:00Z